AB122 Platform Study

This is a phase 1, non-randomized open-label, multicenter platform study designed to evaluate the tolerability and safety of AB122 in patients with malignancies specified in each cohort.

Trial Details

NCT ID
NCT04999761
Phase
PHASE1
Sponsor
Taiho Pharmaceutical Co., Ltd.
Status
RECRUITING
Cancer Type
Adenocarcinoma Esophageal Cancer
Interventions
  • AB122
  • TAS-116
  • TAS-120
  • TAS-115
  • TAS-102
  • Ramucirumab
Locations (sample)
  • Aichi, Japan|32.51879,130.62158
  • Chiba, Japan|35.6,140.11667
  • Ehime, Japan
  • Hokkaido, Japan
  • Kanagawa, Japan|37.58333,139.91667

Key Eligibility Criteria

  • Is male or female aged ≥ 18 years at the time of informed consent; Willing and able to comply with scheduled visits and study procedures (except fo…
  • Has an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 before administration of study treatment;
  • Has adequate organ function as defined by the following criteria:
  • AST and ALT ≤ 3 × ULN; or if a patient with documented liver metastases, AST and ALT ≤ 5 × ULN

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Esophageal Cancer Trials on Trialify →